Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | BCR | P11274 | 1/20 | 0.39 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.38 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.38 |
| ▸ | MITF | O75030 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4989566 | 0.89 | GAA (0.45) | HPGDMEN1KMT2A | |
| SCHEMBL4990813 | 0.88 | PKM (0.42) | HPGDMEN1KMT2AHTTALDH1A1 | |
| SCHEMBL4982974 | 0.86 | GRM5 (0.45) | — | |
| SCHEMBL4988052 | 0.86 | HSP90AB1 (0.42) | HPGDKMT2AALDH1A1 | |
| SCHEMBL4985620 | 0.85 | PTGS1 (0.43) | HPGD | |
| SCHEMBL4987144 | 0.85 | CYP2C9 (0.40) | HPGDSMN1; SMN2MEN1KMT2AHTT | |
| SCHEMBL4989543 | 0.85 | HPGD (0.45) | HPGDALDH1A1 | |
| SCHEMBL4984723 | 0.84 | GRM5 (0.43) | ALDH1A1 | |
| SCHEMBL4993556 | 0.82 | EPHX2 (0.42) | — | |
| SCHEMBL4989388 | 0.81 | MAPK1 (0.55) | HPGDSMN1; SMN2MEN1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2008-02-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | HPGD 368/4885SMN1; SMN2 4369/4885MEN1 4853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.